| Treatment of Fabry’s disease with the pharmacologic chaperone migalastat DP Germain, DA Hughes, K Nicholls, DG Bichet, R Giugliani, WR Wilcox, ... New england journal of medicine 375 (6), 545-555, 2016 | 587 | 2016 |
| Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry CM Eng, J Fletcher, WR Wilcox, S Waldek, CR Scott, DO Sillence, ... Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2007 | 466 | 2007 |
| Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study DA Hughes, K Nicholls, SP Shankar, G Sunder-Plassmann, D Koeller, ... Journal of medical genetics 54 (4), 288-296, 2017 | 429 | 2017 |
| Efficacy and safety of abatacept in lupus nephritis: a twelve‐month, randomized, double‐blind study R Furie, K Nicholls, TT Cheng, F Houssiau, R Burgos‐Vargas, SL Chen, ... Arthritis & rheumatology 66 (2), 379-389, 2014 | 363 | 2014 |
| Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial S Zoungas, BP McGrath, P Branley, PG Kerr, C Muske, R Wolfe, ... Journal of the American College of Cardiology 47 (6), 1108-1116, 2006 | 309 | 2006 |
| The clinical course of mesangial IgA associated nephropathy in adults KM NICHOLLS, KF FAIRLEY, JP DOWLING, P KINCAID-SMITH QJM: An International Journal of Medicine 53 (2), 227-250, 1984 | 254 | 1984 |
| Agalsidase alfa and kidney dysfunction in Fabry disease M West, K Nicholls, A Mehta, JTR Clarke, R Steiner, M Beck, BA Barshop, ... Journal of the American Society of Nephrology 20 (5), 1132-1139, 2009 | 221 | 2009 |
| Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry MR Patel, F Cecchi, M Cizmarik, I Kantola, A Linhart, K Nicholls, ... Journal of the American College of Cardiology 57 (9), 1093-1099, 2011 | 188 | 2011 |
| Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference R Schiffmann, DA Hughes, GE Linthorst, A Ortiz, E Svarstad, DG Warnock, ... Kidney international 91 (2), 284-293, 2017 | 187 | 2017 |
| Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. K Nicholls, TE Mandel Laboratory Investigation; a Journal of Technical Methods and Pathology 60 (4 …, 1989 | 168 | 1989 |
| Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 … DP Germain, R Giugliani, DA Hughes, A Mehta, K Nicholls, L Barisoni, ... Orphanet journal of rare diseases 7, 1-11, 2012 | 165 | 2012 |
| Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central … KM Nicholls, MD Shapiro, VJ Van Putten, R Kluge, HM Chung, DG Bichet, ... Circulation research 56 (3), 457-461, 1985 | 148 | 1985 |
| Effects of enzyme replacement therapy in Fabry disease—a comprehensive review of the medical literature O Lidove, ML West, G Pintos-Morell, R Reisin, K Nicholls, LE Figuera, ... Genetics in Medicine 12 (11), 668-679, 2010 | 147 | 2010 |
| Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial J Lv, MG Wong, MA Hladunewich, V Jha, LS Hooi, H Monaghan, M Zhao, ... Jama 327 (19), 1888-1898, 2022 | 141 | 2022 |
| Renal dialysis abatement: lessons from a social study M Ashby, C Hoog, A Kellehear, PG Kerr, D Brooks, K Nicholls, M Forrest Palliative medicine 19 (5), 389-396, 2005 | 141 | 2005 |
| HLA-DQA1 and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome RA Gbadegesin, A Adeyemo, NJA Webb, LA Greenbaum, ... Journal of the American Society of Nephrology 26 (7), 1701-1710, 2015 | 137 | 2015 |
| Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre TT Nguyen, T Gin, K Nicholls, M Low, J Galanos, A Crawford Clinical & experimental ophthalmology 33 (2), 164-168, 2005 | 129 | 2005 |
| Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the … DP Germain, K Nicholls, R Giugliani, DG Bichet, DA Hughes, LM Barisoni, ... Genetics in Medicine 21 (9), 1987-1997, 2019 | 126 | 2019 |
| A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects R Giugliani, S Waldek, DP Germain, K Nicholls, DG Bichet, JK Simosky, ... Molecular Genetics and Metabolism 109 (1), 86-92, 2013 | 126 | 2013 |
| Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients MD Shapiro, KM Nicholls, BM Groves, R Kluge, HM Chung, DG Bichet, ... Kidney international 28 (2), 206-211, 1985 | 125 | 1985 |
Derralynn HughesUCLVerifierad e-postadress på ucl.ac.uk
